OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
CUBE$2.4659

Cube Labs SpA

Investment Management & Fund OperatorsVerified

Cube Labs SpA exhibits a capital structure with a market cap of EUR 50.2 million and a price-to-book ratio of 0.85, indicating a discount to tangible book value. The company's liquidity position is characterized by EUR 1.21 million in cash and equivalents, but with a negative net cash position after subtracting total debt of EUR 2.86 million. The current ratio of 1.16 suggests limited short-term liquidity coverage. Profitability metrics show a challenging performance, with a return on equity of -1.23% and a return on assets of -1.15%. The company reported a net loss of EUR 730,750 and an operating loss of EUR 803,140, indicating a lack of operational profitability. These results fall below the typical performance of investment management firms, which usually exhibit positive returns on equity and assets. The company's revenue of EUR 2.01 million is not segmented by geographic region or business line in the provided data, making it difficult to assess revenue concentration. However, the venture builder model implies a focus on innovation and R&D, with potential exposure to global healthcare technology markets. Growth trajectory is not clearly defined in the data, as the outlook for the current and next fiscal years is not provided. The company's operating cash flow of -EUR 1.91 million and free cash flow of -EUR 0.94 million suggest ongoing cash burn, which could limit its ability to scale operations or fund new ventures without external financing. Risk factors include a medium liquidity risk due to the negative net cash position and a current ratio below 2.0. The dilution risk is assessed as low, with no near-term pressure expected. However, the company's capital expenditure of -EUR 0.22 million and ongoing losses may necessitate future financing, which could lead to dilution. Recent events include a strong buy recommendation from one analyst with a mean price target of EUR 3.25, indicating potential upside despite the company's current unprofitable status. No recent filings or transcripts are provided to detail strategic shifts or operational updates.

30-day price · CUBE+0.14 (+6.0%)
Low$2.32High$2.46Close$2.46As of10 May, 00:00 UTC
Profile
CompanyCube Labs SpA
TickerCUBE.MI
SectorFinancials
BusinessBanking & Investment Services
Industry groupBanking & Investment Services
IndustryInvestment Management & Fund Operators
AI analysis

Business. Cube Labs SpA is an Italy-based venture builder primarily engaged in the healthcare technology industry, creating business from R&D stage and providing entrepreneurial and operational support into healthcare management and technology solutions.

Classification. Cube Labs SpA is classified under the Financials sector, specifically in the Investment Management & Fund Operators industry, with a confidence level of 0.92.

Cube Labs SpA exhibits a capital structure with a market cap of EUR 50.2 million and a price-to-book ratio of 0.85, indicating a discount to tangible book value. The company's liquidity position is characterized by EUR 1.21 million in cash and equivalents, but with a negative net cash position after subtracting total debt of EUR 2.86 million. The current ratio of 1.16 suggests limited short-term liquidity coverage. Profitability metrics show a challenging performance, with a return on equity of -1.23% and a return on assets of -1.15%. The company reported a net loss of EUR 730,750 and an operating loss of EUR 803,140, indicating a lack of operational profitability. These results fall below the typical performance of investment management firms, which usually exhibit positive returns on equity and assets. The company's revenue of EUR 2.01 million is not segmented by geographic region or business line in the provided data, making it difficult to assess revenue concentration. However, the venture builder model implies a focus on innovation and R&D, with potential exposure to global healthcare technology markets. Growth trajectory is not clearly defined in the data, as the outlook for the current and next fiscal years is not provided. The company's operating cash flow of -EUR 1.91 million and free cash flow of -EUR 0.94 million suggest ongoing cash burn, which could limit its ability to scale operations or fund new ventures without external financing. Risk factors include a medium liquidity risk due to the negative net cash position and a current ratio below 2.0. The dilution risk is assessed as low, with no near-term pressure expected. However, the company's capital expenditure of -EUR 0.22 million and ongoing losses may necessitate future financing, which could lead to dilution. Recent events include a strong buy recommendation from one analyst with a mean price target of EUR 3.25, indicating potential upside despite the company's current unprofitable status. No recent filings or transcripts are provided to detail strategic shifts or operational updates.
Key takeaways
  • Cube Labs SpA is a venture builder in healthcare technology with a capital structure showing a discount to book value.
  • The company is unprofitable, with negative returns on equity and assets, and a net loss in the latest reporting period.
  • Liquidity is constrained by a negative net cash position and a current ratio of 1.16.
  • Analysts have issued a strong buy recommendation with a price target of EUR 3.25, suggesting potential for value creation.
  • The company's growth trajectory is unclear, with no detailed outlook provided for the current or next fiscal year.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyEUR
Revenue$2.0M
Gross profit$224.2k
Operating income-$803.1k
Net income-$730.8k
R&D
SG&A
D&A
SBC
Operating cash flow-$1.9M
CapEx-$216.4k
Free cash flow-$940.4k
Total assets$63.5M
Total liabilities$4.2M
Total equity$59.4M
Cash & equivalents$1.2M
Long-term debt$2.9M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$2.46
Market cap$50.2M
Enterprise value$51.8M
P/E
Reported non-GAAP P/E
EV/Revenue25.8
EV/Op income
EV/OCF
P/B0.8
P/Tangible book0.8
Tangible book$59.4M
Net cash-$1.6M
Current ratio1.2
Debt/Equity0.1
ROA-1.1%
ROE-1.2%
Cash conversion2.6%
CapEx/Revenue-10.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Banking & Investment Services · cohort 10 companies
MetricCUBEActivity
Op margin-40.0%26.6% medp25 13.9% · p75 29.0%bottom quartile
Net margin-36.4%18.8% medp25 13.7% · p75 22.7%bottom quartile
Gross margin11.2%67.6% medp25 41.5% · p75 93.2%bottom quartile
CapEx / revenue-10.8%1.2% medp25 0.4% · p75 1.9%bottom quartile
Debt / equity5.0%7.7% medp25 7.7% · p75 7.7%bottom quartile
Observations
IR observations
Mean price target3.25 EUR
Median price target3.25 EUR
High price target3.25 EUR
Low price target3.25 EUR
Mean recommendation1.00 (1=strong buy, 5=strong sell)
Strong-buy count1.00
Buy count0.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 03:56 UTC#6abcdcd0
Market quoteclose EUR 2.46 · shares 0.02B diluted
no public URL
2026-05-10 03:56 UTC#0dc8596d
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 03:58 UTCJob: 0dae7234